Is Compugen Ltd. (CGEN) a Buy, Sell, or Hold?
Compugen Ltd.
NASDAQ:CGEN
$2.3 USD
$0 (0.0%)
- Volume
- 141.88K
- Average Volume
- 485.85K
- Market Capitalization
- $217.47M
- P/E Ratio
- 6.27
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.24
- Year Low
- $1.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.23
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eran Ophir |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CGEN |
| CUSIP | M25722105 |
| CIK | 0001119774 |
| Web | https://cgen.com |
| Phone | 972 3 765 8585 |
| Currency | USD |
| Employees | 75 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.23 |
| Quick Ratio | 6.23 |
| Cash Ratio | 0.56 |
Sales & Book Value
| Annual Sales | $72.76M |
| Price / Sales | 2.99 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | 2.28 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -54.00% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.38 |
| Trailing P/E Ratio | 6.27 |
| PEG Ratio | 0.23 |
| P/E Growth | 0.23 |
| Net Income | $35.34M |
| Net Margin | 47.97% |
| Pretax Margin | 48.01% |
| Return on Equity | 47.72% |
| Return on Assets | 23.90% |
Financials Score
| AltmanZ Score | 4.82 |
| Piotroski Score | 5.00 |
| Working Capital | 115.25M |
| Total Assets | 145.86M |
| Ebit | 34.88M |
| Market Cap | 217.47M |
| Total Liabilities | 50.51M |
Poll Results
About Compugen Ltd. (NASDAQ:CGEN) Stock
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific anti ... body targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
2026-06-18 07:00:00
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark.
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
2026-06-15 13:12:14
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
2026-06-11 07:00:00
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark.
2026-06-08 07:00:00
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET.
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
2026-05-19 08:17:23
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027.
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
2026-05-18 12:00:51
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Q1 Earnings Call Highlights
2026-05-18 10:09:13
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs.
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
2026-05-18 10:00:49
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago.
Frequently Asked Questions
-
What is the current Compugen Ltd. (CGEN) stock price?
-
Compugen Ltd.(NASDAQ:CGEN) stock price is $2.3 in the last trading session. During the trading session, CGEN stock reached the peak price of $3.24 while $1.3 was the lowest point it dropped to. The percentage change in CGEN stock occurred in the recent session was 0.0% while the dollar amount for the price change in CGEN stock was $0.
-
CGEN's industry and sector of operation?
-
The NASDAQ listed CGEN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CGEN?
-
Anat Cohen-Dayag | Executive Chair
Eran Ophir | Chief Executive Officer, President & Director
Zurit Levine | Senior Vice President of Business Development
David Silberman | Chief Financial Officer
Eran Ben Dor | General Counsel & Corporate Secretary -
How many employees does CGEN have?
-
Number of CGEN employees currently stands at 75. CGEN operates from Azrieli Center, Holon, TA 5885849, IL.
-
Link for CGEN official website?
-
Official Website of CGEN is: https://cgen.com
-
How do I contact CGEN?
-
CGEN could be contacted at phone #972 3 765 8585 and can also be accessed through its website. CGEN operates from Azrieli Center, Holon, TA 5885849, IL.
-
How many shares of CGEN are traded daily?
-
The average number of CGEN shares traded daily for last 3 months was 485.85K.
-
What is the market cap of CGEN currently?
-
The market value of CGEN currently stands at $217.47M with its latest stock price at $2.3